Update on primary sclerosing cholangitis genetics

Current Opinion in Gastroenterology

Volumn 30, Issue 3, 2014, Pages 310-319

  Henriksen, Eva K K ^a,b   Melum, Espen ^a,b   Karlsen, Tom H ^a,b,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF BERGEN   (Norway)

Author keywords

genome wide association study; primary sclerosing cholangitis

Indexed keywords

ALKALINE PHOSPHATASE; HISTONE DEACETYLASE 7; INTERFERON REGULATORY FACTOR 4; LYMPHOID ENHANCER FACTOR 1;

CHROMOSOME 3P; CHROMOSOME 6P; CROHN DISEASE; ENVIRONMENTAL FACTOR; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC RISK; GENETIC VARIABILITY; GENETICS; HLA SYSTEM; HUMAN; IMMUNOREGULATION; MAJOR HISTOCOMPATIBILITY COMPLEX; PATHOPHYSIOLOGY; PHENOTYPE; PLEIOTROPY; PRIMARY SCLEROSING CHOLANGITIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSLATIONAL RESEARCH; ULCERATIVE COLITIS; ANIMAL; DISEASE MODEL; GENETIC PREDISPOSITION; MOUSE; PROCEDURES; SCLEROSING CHOLANGITIS;

ANIMALS; CHOLANGITIS, SCLEROSING; DISEASE MODELS, ANIMAL; GENETIC PLEIOTROPY; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MICE; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84898547044     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0000000000000052     Document Type: Review

References (91)

1. Bergquist A, Montgomery SM, Bahmanyar S, et al. Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2008; 6:939-943.
2. Karlsen TH, Franke A, Melum E, et al. Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology 2010; 138:1102-1111.
3. Melum E, Franke A, Schramm C, et al. Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat Genet 2011; 43:17-19.
4. Srivastava B, Mells GF, Cordell HJ, et al. Fine mapping and replication of genetic risk loci in primary sclerosing cholangitis. Scand J Gastroenterol 2012; 47:820-826.
5. Folseraas T, Melum E, Rausch P, et al. Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci. J Hepatol 2012; 57:366-375.
6. Ellinghaus D, Folseraas T, Holm K, et al. Genome-wide association analysis in primary sclerosing cholangitis and ulcerative colitis identifies risk loci at GPR35 and TCF4. Hepatology 2013; 58:1074-1083.
7. Liu JZ, Hov JR, Folseraas T, et al. Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet 2013; 45:670-675.
8. Kim WK, Park JS, Sul OJ, et al. Role of TNFR-related 2 mediated immune responses in dextran sulfate sodium-induced inflammatory bowel disease. Mol Cells 2011; 31:99-104.
9. Wang Y, Subudhi SK, Anders RA, et al the role of herpesvirus entry mediator as a negative regulator of T cell-mediated responses. J Clin Invest 2005; 115:711-717.
10. Kim WK, Sul OJ, Choi EK, et al. Absence of herpes virus entry mediator (HVEM) increases bone mass by attenuating receptor activator of nuclear factor-kappaB ligand (RANKL)-induced osteoclastogenesis. Endocrinology 2012; 153:4808-4817.
11. Karaba AH, Kopp SJ, Longnecker R. Herpesvirus entry mediator is a serotype specific determinant of pathogenesis in ocular herpes. Proc Natl Acad Sci USA 2012; 109:20649-20654.
12. Sakoda Y, Anand S, Zhao Y, et al. Herpesvirus entry mediator regulates hypoxia-inducible factor-1alpha and erythropoiesis in mice. J Clin Invest 2011; 121:4810-4819.
13. Kim HJ, Kim HM, Kim CS, et al. HVEM-deficient mice fed a high-fat diet are protected from adipose tissue inflammation and glucose intolerance. FEBS Lett 2011; 585:2285-2290.
14. Wahl C, Wegenka UM, Leithauser F, et al. IL-22-dependent attenuation of T cell-dependent (ConA) hepatitis in herpes virus entry mediator deficiency. J Immunol 2009; 182:4521-4528.
15. Carpentier M, Guillemette C, Bailey JL, et al. Reduced fertility in male mice deficient in the zinc metallopeptidase NL1. Mol Cellular Biol 2004; 24:4428-4437.
16. Hafez D, Huang JY, Huynh AM, et al. Neprilysin-2 is an important beta-amyloid degrading enzyme. Am J Pathol 2011; 178:306-312.
17. Bouillet P, Metcalf D, Huang DC, et al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 1999; 286:1735-1738.
18. Lauer C, Brunner T, Corazza N the proapoptotic Bcl-2 family member Bim plays a central role during the development of virus-induced hepatitis. J Immunol 2012; 188:916-922.
19. Corazza N, Jakob S, Schaer C, et al. TRAIL receptor-mediated JNK activation and Bim phosphorylation critically regulate Fas-mediated liver damage and lethality. J Clin Invest 2006; 116:2493-2499.
20. Shahinian A, Pfeffer K, Lee KP, et al. Differential T cell costimulatory requirements in CD28-deficient mice. Science 1993; 261:609-612.
21. Min KD, Asakura M, Liao Y, et al. Identification of genes related to heart failure using global gene expression profiling of human failing myocardium. Biochem Biophys Res Commun 2010; 393:55-60.
22. Bezerra JA, Carrick TL, Degen JL, et al. Biological effects of targeted inactivation of hepatocyte growth factor-like protein in mice. J Clin Invest 1998; 101:1175-1183.
23. Lohler J, Sadlack B, Schorle H, et al. Generalized autoimmune diseases in BALB/c mice with a genetically dependent interleukin-2 deficiency. Verh Dtsch Ges Pathol 1996; 80:293-296.
24. Sadlack B, Merz H, Schorle H, et al. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993; 75:253-261.
25. Horak I. Immunodeficiency inIL-2-knockout mice. Clin Immunol Immunopathol 1995; 76:S172-173.
26. Schultz M, Clarke SH, Arnold LW, et al. Disrupted B-lymphocyte development and survival in interleukin-2-deficient mice. Immunology 2001; 104:127-134.
27. Schultz M, Tonkonogy SL, Sellon RK, et al. IL-2-deficient mice raised under germfree conditions develop delayed mild focal intestinal inflammation. Am J Physiol 1999; 276:G1461-1472.
28. Cousens LP, Orange JS, Biron CA. Endogenous IL-2 contributes to T cell expansion and IFN-gamma production during lymphocytic choriomeningitis virus infection. J Immunol 1995; 155:5690-5699.
29. Shang XZ, Ma KY, Radewonuk J, et al. IgE isotype switch and IgE production are enhanced in IL-21-deficient but not IFN-gamma-deficient mice in a Th2-biased response. Cell Immunol 2006; 241:66-74.
30. Muto A, Tashiro S, Nakajima O, et al the transcriptional programme of antibody class switching involves the repressor Bach2. Nature 2004; 429:566-571.
31. Nakamura A, Ebina-Shibuya R, Itoh-Nakadai A, et al. Transcription repressor Bach2 is required for pulmonary surfactant homeostasis and alveolar macro-phage function. J Exp Med 2013; 210:2191-2204.
32. Roychoudhuri R, Hirahara K, Mousavi K, et al. BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis. Nature 2013; 498:506-510.
33. Willerford DM, Chen J, Ferry JA, et al. Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity 1995; 3:521-530.
34. Sasaki T, Takemori H, Yagita Y, et al. SIK2 is a key regulator for neuronal survival after ischemia via TORC1-CREB. Neuron 2011; 69:106-119.
35. Chang S, Young BD, Li S, et al. Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell 2006; 126:321-334.
36. Jin Z, Wei W, Dechow PC, Wan Y. HDAC7 inhibits osteoclastogenesis by reversing RANKL-triggered beta-catenin switch. Mol Endocrinol 2013; 27:325-335.
37. Velazquez L, Cheng AM, Fleming HE, et al. Cytokine signaling and hemato-poietic homeostasis are disrupted in Lnk-deficient mice. J Exp Med 2002; 195:1599-1611.
38. Louria-Hayon I, Frelin C, Ruston J, et al. Lnk adaptor suppresses radiation resistance and radiation-induced B-cell malignancies by inhibiting IL-11 signaling. Proc Natl Acad Sci USA 2013; 110:20599-20604.
39. Huynh DP, Maalouf M, Silva AJ, et al. Dissociated fear and spatial learning in mice with deficiency of ataxin-2. PloS One 2009; 4:e6235.
40. Kiehl TR, Nechiporuk A, Figueroa KP, et al. Generation and characterization of Sca2 (ataxin-2) knockout mice. Biochem Biophys Res Commun 2006; 339:17-24.
41. Lastres-Becker I, Brodesser S, Lutjohann D, et al. Insulin receptor and lipid metabolism pathology in ataxin-2 knock-out mice. Hum Mol Genet 2008; 17:1465-1481.
42. Zhuang Y, Cheng P, Weintraub H. B-lymphocyte development is regulated by the combined dosage of three basic helix-loop-helix genes, E2A, E2-2, and HEB. Mol Cell Biol 1996; 16:2898-2905.
43. Flora A, Garcia JJ, Thaller C, Zoghbi HY the E-protein Tcf4 interacts with Math1 to regulate differentiation of a specific subset of neuronal progenitors. Proc Natl Acad Sci USA 2007; 104:15382-15387.
44. Cisse B, Caton ML, Lehner M, et al. Transcription factor E2-2 is an essential and specific regulator of plasmacytoid dendritic cell development. Cell 2008; 135:37-48.
45. Iguchi-Manaka A, Kai H, Yamashita Y, et al. Accelerated tumor growth in mice deficient in DNAM-1 receptor. J Exp Med 2008; 205:2959-2964.
46. Welch MJ, Teijaro JR, Lewicki HA, et al. CD8 T cell defect of TNF-alpha and IL-2 in DNAM-1 deficient mice delays clearance in vivo of a persistent virus infection. Virology 2012; 429:163-170.
47. Matthews SA, Navarro MN, Sinclair LV, et al. Unique functions for protein kinase D1 and protein kinase D2 in mammalian cells. Biochem J 2010; 432:153-163.
48. Sasaki K, Hamazaki J, Koike M, et al. PAC1 gene knockout revealsanessential role of chaperone-mediated 20S proteasome biogenesis and latent 20S proteasomes in cellular homeostasis. Mol Cell Biol 2010; 30:3864-3874.
49. Mells GF, Kaser A, Karlsen TH. Novel insights into autoimmune liver diseases provided by genome-wide association studies. J Autoimmun 2013; 46:41-54.
50. Yoneno K, Hisamatsu T, Shimamura K, et al. TGR5 signalling inhibits the production of pro-inflammatory cytokines by in vitro differentiated inflammatory and intestinal macrophages in Crohn's disease. Immunology 2013; 139:19-29.
51. McMahan RH, Wang XX, Cheng LL, et al. Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease. J Biol Chem 2013; 288:11761-11770.
52. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012; 491:119-124.
53. McGovern DP, Gardet A, Torkvist L, et al. Genome-wideassociation identifies multiple ulcerative colitis susceptibility loci. Nat Genet 2010; 42:332-337.
54. Barrett JC, Lee JC, Lees CW, et al. Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nat Genet 2009; 41:1330-1334.
55. Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008; 40:955-962.
56. The Wellcome Trust Case Control Consortium. Genome-wide association study of 14000 cases of seven common diseases and 3000 shared controls. Nature 2007; 447:661-678.
57. Andreassen OA, Djurovic S, Thompson WK, et al. Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factors. Am J Hum Genet 2013; 92:197-209.
58. Andreassen OA, Thompson WK, Schork AJ, et al. Improved detection of common variants associated with schizophrenia and bipolar disorder using pleiotropy-informed conditional false discovery rate. PLoS Genet 2013; 9:e1003455.
59. Hov JR, Keitel V, Laerdahl JK, et al. Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis. PLoS One 2010; 5:e12403.
60. Lango Allen H, Estrada K, Lettre G, et al. Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature 2010; 467:832-838.
61. Wannhoff A, Hov JR, Folseraas T, et al. FUT2 and FUT3 genotype determines CA19-9 cut-off values for detection of cholangiocarcinoma in patients with primary sclerosing cholangitis. J Hepatol 2013; 59:1278-1284.
62. Yuan X, Waterworth D, Perry JR, et al. Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. Am J Hum Genet 2008; 83:520-528.
63. Chambers JC, Zhang W, Sehmi J, et al. Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nat Genet 2011; 43:1131-1138.
64. Weiss KM, Terwilliger JD. How many diseases does ittake to map a gene with SNPs? Nat Genet 2000; 26:151-157.
65. Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010; 42:1118-1125.
66. McCarthy MI, Abecasis GR, Cardon LR, et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet 2008; 9:356-369.
67. Karlsen TH, Melum E, Franke A the utility of genome-wide association studies in hepatology. Hepatology 2010; 51:1833-1842.
68. Eichler EE, Flint J, Gibson G, et al. Missing heritability and strategies for finding the underlying causes of complex disease. Nat Rev Genet 2010; 11:446-450.
69. Cagliani R, Pozzoli U, Forni D, et al. Crohn's disease loci are common targets of protozoa-driven selection. Mol Biol Evol 2013; 30:1077-1087.
70. Sabeti PC, Reich DE, Higgins JM, et al. Detecting recent positive selection in the human genome from haplotype structure. Nature 2002; 419:832-837.
71. Trynka G, Hunt KA, Bockett NA, et al. Dense genotyping identifies and localizes multiple common and rare variant association signals in celiac disease. Nat Genet 2011; 43:1193-1201.
72. Sollid LM, Jabri B. Triggers and drivers of autoimmunity: lessons from coeliac disease. Nat Rev Immunol 2013; 13:294-302.
73. Ricano-Ponce I, Wijmenga C. Mapping of immune-mediated disease genes. Ann Rev Genomics Hum Genet 2013; 14:325-353.
74. Stahl EA, Wegmann D, Trynka G, et al. Bayesian inference analyses of the polygenic architecture of rheumatoid arthritis. Nat Genet 2012; 44:483-489.
75. Ardlie KG, Kruglyak L, Seielstad M. Patterns of linkage disequilibrium in the human genome. Nat Rev Genet 2002; 3:299-309.
76. Horton R, Wilming L, Rand V, et al. Gene map of the extended human MHC. Nat Rev Genet 2004; 5:889-899.
77. Oksenberg JR, Barcellos LF, Cree BA, et al. Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans. Am J Hum Genet 2004; 74:160-167.
78. Schork AJ, Thompson WK, Pham P, et al. All SNPs are not created equal: genome-wide association studies reveal a consistent pattern of enrichment among functionally annotated SNPs. PLoS Genet 2013; 9:e1003449.
79. Gerstein MB, Kundaje A, Hariharan M, et al. Architecture of the human regulatory network derived from ENCODE data. Nature 2012; 489:91-100.
80. Maurano MT, Humbert R, Rynes E, et al. Systematic localization of common disease-associated variation in regulatory DNA. Science 2012; 337:1190-1195.
81. Mitro N, Godio C, De Fabiani E, et al. Insights in the regulation of cholesterol 7alpha-hydroxylase gene reveal a target for modulating bile acid synthesis. Hepatology 2007; 46:885-897.
82. Dequiedt F, Kasler H, Fischle W, et al. HDAC7, a thymus-specific class II histone deacetylase, regulates Nur77 transcription and TCR-mediated apop-tosis. Immunity 2003; 18:687-698.
83. Hov JR, Kosmoliaptsis V, Traherne JA, et al. Electrostatic modifications of the human leukocyte antigen-DR P9 peptide-binding pocket and susceptibility to primary sclerosing cholangitis. Hepatology 2011; 53:1967-1976.
84. Prokunina-Olsson L, Muchmore B, Tang W, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 2013; 45:164-171.
85. Adolph TE, Tomczak MF, Niederreiter L, et al. Paneth cells as a site of origin for intestinal inflammation. Nature 2013; 503:272-276.
86. Hunt KA, Mistry V, Bockett NA, et al. Negligible impact ofrare autoimmune-locus coding-region variants on missing heritability. Nature 2013; 498:232-235.
87. Ellinghaus D, Zhang H, Zeissig S, et al. Association between variants of PRDM1 and NDP52 and Crohn's disease, based on exome sequencing and functional studies. Gastroenterology 2013; 145:339-347.
88. Jiao Y, Pawlik TM, Anders RA, et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholan-giocarcinomas. Nat Genet 2013; 45:1470-1473.
89. Timmer MR, Beuers U, Fockens P, et al. Genetic and epigenetic abnormalities in primary sclerosing cholangitis-associated cholangiocarcinoma. Inflamm Bowel Dis 2013; 19:1789-1797.
90. Sayin SI, Wahlstrom A, Felin J, et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 2013; 17:225-235.
91. Devkota S, Wang Y, Musch MW, et al. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-/-mice. Nature 2012; 487:104-108.